COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
Join AHA and the Centers for Disease Control and Prevention Friday at 2 p.m. ET for a Project Firstline conversation on caring safely for COVID-19 patients.
The Food and Drug Administration issued an emergency use authorization for the Lucira COVID-19 All-In-One Test Kit, the first rapid test to detect the COVID-19 virus that one can administer completely at home when prescribed by a health care provider to individuals age 14 or older.
The Department of Health and Human Services (HHS) today issued two important clarifications related to Provider Relief Fund (PRF) reporting.
This document requests action to spur Congress to fully reinstate June reporting requirements for the COVID-19 Provider Relief Fund during its ‘lame-duck session.’
Please join AHA and the Centers for Disease Control and Prevention (CDC) for a conversation on providing safe care to COVID-19 positive patients in various settings on Friday, November 20, 2020 at 2 p.m. ET. Dr. Michael Bell, deputy director of the division of health care quality promotion at the…
The Food and Drug Administration issued final guidance for health care providers and researchers using investigational COVID-19 convalescent plasma, defined as convalescent plasma that does not meet all conditions of the agency’s emergency use authorization or which is used under an investigational…
The recently launched AHA Living Learning Network (LLN) provides essential resources through a peer-to-peer community of health care professionals dedicated to helping hospitals and health systems recover, rebuild and reimagine health care while responding to the pandemic.
The AHA will host a call today, Nov. 16, from 4-5 p.m. ET with leaders from the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and other federal agencies to discuss the delivery and administration of monoclonal antibody therapies.
The Centers for Medicare & Medicaid Services announced Medicare coverage for monoclonal antibody therapies, with no beneficiary cost-sharing for the duration of the COVID-19 public health emergency. CMS said the coverage will apply to bamlanivimab, the Lilly therapeutic that earned an emergency…
The Food and Drug Administration Nov. 10 issued an emergency use authorization for Eli Lilly and Company’s monoclonal antibody therapy, bamlanivimab.